Features | Partner Sites | Information | LinkXpress
Sign In
SEEGENE
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Abbott Expands Agreement with GlaxoSmithKline to Develop Companion Diagnostic

By Labmedica International staff writers
Posted on 15 Dec 2011
Abbott (Abbott Park, IL, USA) will expand its existing agreement with GlaxoSmithKline Biologicals (GSK; Brentford, United Kingdom) to include the development of an additional companion diagnostic test for a cancer immunotherapy antigen.

The existing agreements between the two companies focused on the development of PCR tests to screen non-small-cell lung cancer and melanoma tumors for expression of the MAGE-A3 antigen. MAGE-A3 is a tumor-specific antigen that is expressed in a large variety of cancers, including melanoma, non-small-cell lung, head and neck, and bladder cancer, with no expression in normal cells. Expression of the MAGE-A3 gene has been observed in testicular cells but without antigen presentation capabilities.

Under the expanded agreement, Abbott will develop a polymerase chain reaction (PCR) test for use on the Abbott m2000rt instrument to screen non-small-cell lung cancer tumors for expression of the PRAME antigen. PRAME is a preferentially expressed antigen of melanoma that is expressed in 69 % of non-small-cell lung cancer cases, as well as in a wide variety of cancer types, including melanoma, breast, ovarian, and bladder cancer, with limited expression in normal cells.

Abbott is a pioneer in the use of molecular tests based on PCR and fluorescence in situ hybridization (FISH) technologies to aid clinicians in the selection of appropriate pharmacogenomic therapies.

GSK’s Antigen Specific Cancer Immunotherapy Program (ASCI) is investigated in the clinic to support their use to reduce the risk of tumor recurrence following surgery, or to impact tumor growth in an early metastatic setting. The highly specific mode of action of GSK’s ASCIs allows development of diagnostic tools to aid in selecting patients eligible for the treatment, depending on the expression of the tumor antigens.

Related Links:

Abbott
GlaxoSmithKline Biologicals



PURITAN MEDICAL
GREINER-BIO-ONE
ADVANCED INSTRUMENTS
BioConferenceLive

Channels

Genetic Tests

view channel
Image: The QuantiTect Reverse Transcription Kit (Photo courtesy of Qiagen)

Blood Tests Predict Risk of Sudden Cardiac Death

A simple blood test can predict a person's risk for sudden cardiac death, enabling physicians to quickly and accurately assess a patient's need for an implantable cardiac defibrillator (ICD).... Read more

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.